These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 23232293)

  • 1. Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers.
    Shaffer JL; Petrella JR; Sheldon FC; Choudhury KR; Calhoun VD; Coleman RE; Doraiswamy PM;
    Radiology; 2013 Feb; 266(2):583-91. PubMed ID: 23232293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease.
    Karow DS; McEvoy LK; Fennema-Notestine C; Hagler DJ; Jennings RG; Brewer JB; Hoh CK; Dale AM;
    Radiology; 2010 Sep; 256(3):932-42. PubMed ID: 20720076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing predictors of conversion and decline in mild cognitive impairment.
    Landau SM; Harvey D; Madison CM; Reiman EM; Foster NL; Aisen PS; Petersen RC; Shaw LM; Trojanowski JQ; Jack CR; Weiner MW; Jagust WJ;
    Neurology; 2010 Jul; 75(3):230-8. PubMed ID: 20592257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
    Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
    PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal change of biomarkers in cognitive decline.
    Lo RY; Hubbard AE; Shaw LM; Trojanowski JQ; Petersen RC; Aisen PS; Weiner MW; Jagust WJ;
    Arch Neurol; 2011 Oct; 68(10):1257-66. PubMed ID: 21670386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer's disease dementia.
    Arbizu J; Prieto E; Martínez-Lage P; Martí-Climent JM; García-Granero M; Lamet I; Pastor P; Riverol M; Gómez-Isla MT; Peñuelas I; Richter JA; Weiner MW;
    Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1394-405. PubMed ID: 23715905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimodal classification of Alzheimer's disease and mild cognitive impairment.
    Zhang D; Wang Y; Zhou L; Yuan H; Shen D;
    Neuroimage; 2011 Apr; 55(3):856-67. PubMed ID: 21236349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longer-Term Investigation of the Value of 18F-FDG-PET and Magnetic Resonance Imaging for Predicting the Conversion of Mild Cognitive Impairment to Alzheimer's Disease: A Multicenter Study.
    Inui Y; Ito K; Kato T;
    J Alzheimers Dis; 2017; 60(3):877-887. PubMed ID: 28922157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
    Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
    Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.
    Trzepacz PT; Yu P; Sun J; Schuh K; Case M; Witte MM; Hochstetler H; Hake A;
    Neurobiol Aging; 2014 Jan; 35(1):143-51. PubMed ID: 23954175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.
    Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R
    J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis.
    Yuan Y; Gu ZX; Wei WS
    AJNR Am J Neuroradiol; 2009 Feb; 30(2):404-10. PubMed ID: 19001534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of atlas-based MR attenuation correction on the diagnosis of FDG-PET/MR for Alzheimer's diseases- A simulation study combining multi-center data and ADNI-data.
    Sekine T; Buck A; Delso G; Kemp B; Ter Voert EEGW; Huellner M; Veit-Haibach P; Kaushik S; Wiesinger F; Warnock G;
    PLoS One; 2020; 15(6):e0233886. PubMed ID: 32492074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concordance between brain
    Rubí S; Noguera A; Tarongí S; Oporto M; García A; Vico H; Espino A; Picado MJ; Mas A; Peña C; Amer G
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(1):3-8. PubMed ID: 28645685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurobiological correlates of depressive symptoms in people with subjective and mild cognitive impairment.
    Auning E; Selnes P; Grambaite R; Šaltytė Benth J; Haram A; Løvli Stav A; Bjørnerud A; Hessen E; Hol PK; Muftuler løndalen A; Fladby T; Aarsland D
    Acta Psychiatr Scand; 2015 Feb; 131(2):139-47. PubMed ID: 25346330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
    Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
    J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of imaging modalities, brain atlases and feature selection on prediction of Alzheimer's disease.
    Ota K; Oishi N; Ito K; Fukuyama H; ;
    J Neurosci Methods; 2015 Dec; 256():168-83. PubMed ID: 26318777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease.
    Walhovd KB; Fjell AM; Brewer J; McEvoy LK; Fennema-Notestine C; Hagler DJ; Jennings RG; Karow D; Dale AM;
    AJNR Am J Neuroradiol; 2010 Feb; 31(2):347-54. PubMed ID: 20075088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.